IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

Exploring genomic insights in acute lymphoblastic leukaemia treatment

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

Do all hormone sensitive prostate cancers need triplet therapy?

ESMO 2025: Precision medicine in bladder cancer

Best practice in precision medicine for prostate cancer

ctDNA-guided adjuvant atezolizumab improves OS in MIBC

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others